These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 359130)

  • 1. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.
    Benvenuto JA; Lu K; Hall SW; Benjamin RS; Loo TL
    Cancer Res; 1978 Nov; 38(11 Pt 1):3867-70. PubMed ID: 359130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil in mice.
    Fujimoto S; Ishigami H; Minami T; Miyazaki M; Itoh K; Kimura K
    J Natl Cancer Inst; 1979 Aug; 63(2):465-8. PubMed ID: 379401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits.
    Wu AT; Au JL; Sadée W
    Cancer Res; 1978 Jan; 38(1):210-4. PubMed ID: 338145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
    Cao S; Frank C; Shirasaka T; Rustum YM
    Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, antitumor activity, and acute toxicity of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione by oral administration to animals.
    Fujii S; Nakamura Y; Takeda S; Morita K; Sato T; Marunaka T; Kawaguchi Y; Unemi N
    Gan; 1980 Feb; 71(1):30-44. PubMed ID: 6769737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.
    El Sayed YM; Sadée W
    Cancer Res; 1983 Sep; 43(9):4039-44. PubMed ID: 6409396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
    Au JL; Sadée W
    Cancer Res; 1980 Aug; 40(8 Pt 1):2814-9. PubMed ID: 6771006
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biotransformation of ftorafur].
    Kozhukhov AN
    Vopr Med Khim; 1981; 27(2):243-7. PubMed ID: 6792775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine.
    Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H
    Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disposition of ftorafur in rats after intravenous administration.
    Cohen AM
    Drug Metab Dispos; 1975; 3(4):303-8. PubMed ID: 240661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
    Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
    Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [FT-207 and 5-FU concentrations in brain tumor tissues, plasma and CSF after administration of FT-207 suppository].
    Matsuura H; Nakazawa S
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):912-6. PubMed ID: 6426399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
    Kawata S; Noda S; Imai Y; Tamura S; Saitoh R; Miyoshi S; Minami Y; Tarui S
    Gastroenterol Jpn; 1987 Feb; 22(1):55-62. PubMed ID: 3032726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration.
    Au JL; Sadée W
    Cancer Res; 1979 Oct; 39(10):4289-90. PubMed ID: 383283
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.
    El Sayed YM; Sadée W
    Biochem Pharmacol; 1982 Sep; 31(18):3006-8. PubMed ID: 6814451
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
    Toide H; Akiyoshi H; Minato Y; Okuda H; Fujii S
    Gan; 1977 Oct; 68(5):553-60. PubMed ID: 22472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.